Search

Your search keyword '"Letendre, Scott L."' showing total 1,124 results

Search Constraints

Start Over You searched for: Author "Letendre, Scott L." Remove constraint Author: "Letendre, Scott L."
1,124 results on '"Letendre, Scott L."'

Search Results

101. Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations.

102. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy

104. Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults

105. HIV-associated neurocognitive disorder is associated with HIV-1 dual infection

106. The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study

107. Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study

108. Update and New Directions in Therapeutics for Neurological Complications of HIV Infections

109. Fibroblast growth factors 1 and 2 in cerebrospinal fluid are associated with HIV disease, methamphetamine use, and neurocognitive functioning

110. Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era

111. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

112. Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection

113. Complement Component 3 Is Associated with Metabolic Comorbidities in Older HIV-Positive Adults

114. Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia.

115. Associations between Cognition, Gender and Monocyte Activation among HIV Infected Individuals in Nigeria.

116. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment

117. Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection

118. CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease

119. Physical Activity is Associated with Better Neurocognitive and Everyday Functioning Among Older Adults with HIV Disease

120. Methamphetamine Exposure Combined with HIV-1 Disease or gp120 Expression: Comparison of Learning and Executive Functions in Humans and Mice

121. Reply to Haddow et al

122. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study

124. Individualized Texting for Adherence Building (iTAB): Improving Antiretroviral Dose Timing Among HIV-Infected Persons with Co-occurring Bipolar Disorder

125. Antiretroviral therapy reduces neurodegeneration in HIV infection

126. Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people

127. Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice

128. Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment

129. Cytokine secretion from brain macrophages infected with human immunodeficiency virus in vitro and treated with raltegravir

130. A history of alcohol dependence augments HIV-associated neurocognitive deficits in persons aged 60 and older

131. ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects

132. Apathy is associated with white matter abnormalities in anterior, medial brain regions in persons with HIV infection

133. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline

137. The Veterans Aging Cohort Study Index is Associated With Concurrent Risk for Neurocognitive Impairment

138. Visual Function Assessment in Simulated Real-Life Situations in HIV-Infected Subjects

140. Real-world impact of neurocognitive deficits in acute and early HIV infection

141. Dual-mixed HIV-1 coreceptor tropism and HIV-associated neurocognitive deficits

142. Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection

143. Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection

144. Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment

145. HIV-Infected Individuals with Co-occurring Bipolar Disorder Evidence Poor Antiretroviral and Psychiatric Medication Adherence

146. Correlates of HIV and malaria co-infection inSouthern India

148. Clinical factors related to brain structure in HIV: the CHARTER study

149. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

150. Successful cognitive aging in persons living with HIV infection

Catalog

Books, media, physical & digital resources